Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.

doi:10.1158/1078-0432.CCR-23-0956

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 13 Oct 2023

Pascual Javier, Gil-Gil Miguel, Proszek Paula, Zielinski Christoph, Reay Alistair, Ruiz-Borrego Manuel, Cutts Rosalind, Ciruelos Gil Eva M, Feber Andrew, Muñoz-Mateu Montserrat, Swift Claire, Bermejo Begoña, Herranz Jesus, Margeli Vila Mireia, Antón Antonio, Kahan Zsuzsanna, Csöszi Tibor, Liu Yuan, Fernandez-Garcia Daniel, Garcia-Murillas Isaac, Hubank Michael, Turner Nicholas C, Martín Miguel

Abstract excerpt

PURPOSE: Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy. Here, we conducted plasma ctDNA profiling in patients from the PEARL trial comparing palbociclib+fulvestrant versus capecitabine to investigate associations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Fulvestrant

Share to Neoplasm Metastasis

Share to Piperazines

Share to Pyridines

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 37490393
DOI: 10.1158/1078-0432.CCR-23-0956
PMCID: PMC10570672

Genes

TP53
ESR1
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.PMID 37490393Read ↗

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerSemantic proximity Read ↗

Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.Semantic proximity Read ↗

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.Semantic proximity Read ↗

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerSemantic proximity Read ↗

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.Semantic proximity Read ↗

Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 StudySemantic proximity Read ↗

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Semantic proximity Read ↗

Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.Semantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.Semantic proximity Read ↗

Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQSemantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.